TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27050139

Group type: EXPERIMENTAL
Intervention: Intra-articular sprifermin (300 μg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Intra-articular sprifermin (single and multiple doses)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: COMPARATOR
Intervention: Intra-articular sprifermin and Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Intra-articular sprifermin
Number of subjects: 55
Study: 25048494

Group type: EXPERIMENTAL
Intervention: Once-daily tacrolimus (extended-release), converted from twice-daily tacrolimus at 1 month post-transplantation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Twice-daily tacrolimus
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Once-daily tacrolimus
Number of subjects: 60
Study: 22508830

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg plus entinostat 10 mg (EE)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Erlotinib 150 mg plus placebo (EP)
Number of subjects: 132
Study: 20181970

Group type: EXPERIMENTAL
Intervention: Lasofoxifene 0.5 mg/day
Number of subjects: 8556

Group type: EXPERIMENTAL
Intervention: Lasofoxifene 0.25 mg/day
Number of subjects: 8556

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8556
Study: 18042015

Group type: EXPERIMENTAL
Intervention: One-step PCN tube
Number of subjects: 65

Group type: COMPARATOR
Intervention: Multistep fascial dilator system
Number of subjects: 65
Study: 15643700

Group type: EXPERIMENTAL
Intervention: DTP-PRP-T (Hib conjugate) vaccine
Number of subjects: 55073

Group type: COMPARATOR
Intervention: DTP (control group)
Number of subjects: 55073
Study: 11115824

Group type: EXPERIMENTAL
Intervention: Lexipafant (100 mg/24 hours intravenously for seven days)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Lexipafant
Number of subjects: 290
Study: 9531201

Group type: EXPERIMENTAL
Intervention: Operative treatment (suture repair of disrupted ligaments within 72 hours, followed by immobilization in a below-the-knee plaster cast for 6 weeks)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Non-operative treatment (ankle orthosis for 6 weeks)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 146
Study: 8010422

Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Dorsal penile nerve block (DPNB) with additional ventral injection
Number of subjects: 250
Study: 2499490

Group type: EXPERIMENTAL
Intervention: Endobronchial glypressin (1 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intravenous glypressin (1 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Endobronchial glypressin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Intravenous glypressin
Number of subjects: 27
Study: 4947493

Group type: EXPERIMENTAL
Intervention: Isoniazid prophylaxis for 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31512906

Group type: EXPERIMENTAL
Intervention: Combat exposures (CEs) primed by presenting CE questions before MH instruments
Number of subjects: 464

Group type: COMPARATOR
Intervention: Combat exposures (CEs) primed by presenting CE questions after MH instruments
Number of subjects: 464
Study: 31738448

Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5% (5 mL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5% (10 mL)
Number of subjects: 20
Study: 31242925

Group type: EXPERIMENTAL
Intervention: Automated algorithms (Naïve Bayes Classifier, King‐Lu, InSilicoVA, InSilicoVA‐NT, InterVA‐4, SmartVA)
Number of subjects: 9374

Group type: COMPARATOR
Intervention: Physician assignment of cause of death
Number of subjects: 9374
Study: 28576903

Group type: EXPERIMENTAL
Intervention: One Take Charge session
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Two Take Charge sessions 6 weeks apart
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 400
Study: 24534012

Group type: EXPERIMENTAL
Intervention: Dietary glycemic load
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Dietary insulin load
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Reduced energy diet
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Dietary glycemic index and macronutrient content
Number of subjects: 91
Study: 23751748

Group type: EXPERIMENTAL
Intervention: Diagnostic protocol consisting of judgment possible site, determining probable etiology, checking and feedbacks on laboratory test in 12 hours, and reassessment and adjustment treatment in 48-72 hours.
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 65
Study: 20817937

Group type: EXPERIMENTAL
Intervention: Specialist geriatric input
Number of subjects: 225

Group type: COMPARATOR
Intervention: Regular input
Number of subjects: 225
Study: 18655241

Group type: EXPERIMENTAL
Intervention: Trunk muscle endurance training (6-week, 18-session program)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 31
Study: 17039734

Group type: EXPERIMENTAL
Intervention: Preemptive ketorolac
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative ketorolac
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no ketorolac)
Number of subjects: 0
Study: 12725548

Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubinometry (TcB) during phototherapy
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubinometry (TcB) on the unexposed forehead area after phototherapy
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubinometry (TcB) on the exposed forehead and chest during phototherapy
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Post-phototherapy TcB measurements
Number of subjects: 310

Group type: COMPARATOR
Intervention: Control group measurements of TcB
Number of subjects: 310
Study: 10690817

Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL) implantation (n = 616)
Number of subjects: 1229

Group type: COMPARATOR
Intervention: No IOL implantation (n = 613)
Number of subjects: 1229
Study: 9043839

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Simvastatin (combined 20 mg and 40 mg)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 7942516

Group type: EXPERIMENTAL
Intervention: Masks with lenses clouded to give seven levels of visual acuity
Number of subjects: 46
Study: 3280388

Group type: EXPERIMENTAL
Intervention: Charcoal hemoperfusion for 5 or 10 hours daily in trial A (75 patients with grade 3 encephalopathy)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Charcoal hemoperfusion for 10 hours daily in trial B (62 patients with grade 4 encephalopathy)
Number of subjects: 137

Group type: COMPARATOR
Intervention: No-perfusion group in trial B (62 patients with grade 4 encephalopathy)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Etiologic subgroups (acetaminophen, hepatitis A, hepatitis B, presumed non-A, non-B hepatitis, halothane or drug reaction)
Number of subjects: 137
Study: 31823793

Group type: EXPERIMENTAL
Intervention: LLIN utilization
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Living in rural communities
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Younger women (aged < 30 years)
Number of subjects: 629
Study: 30173448

Group type: EXPERIMENTAL
Intervention: Huanshao Capsules (HSC) at the dose of 3 capsules tid for 12 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Wuziyanzong Pills at 6 g bid for 12 weeks
Number of subjects: 200
Study: 26944022

Group type: EXPERIMENTAL
Intervention: Home‐based, Individually‐tailored Physical activity Print (HIPP) intervention
Number of subjects: 84

Group type: COMPARATOR
Intervention: Wellness contact control condition
Number of subjects: 84
Study: 25089280

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with partially hydrolyzed guar gum (PHGG) for 10 months
Number of subjects: 165

Group type: COMPARATOR
Intervention: No maintenance therapy (Control group)
Number of subjects: 165
Study: 22681769

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL), 3-day, twice daily oral administration
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL)
Number of subjects: 549
Study: 19104169

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (0.075 microg x kg x h)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 19
Study: 17879400

Group type: EXPERIMENTAL
Intervention: Combined intravenous and oral antioxidants
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral administration of antioxidants
Number of subjects: 100
Study: 15117604

Group type: EXPERIMENTAL
Intervention: Plasma PlGF levels in pregnancies complicated by preeclampsia
Number of subjects: 177

Group type: COMPARATOR
Intervention: Plasma PlGF levels in normal pregnancies
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Rise in plasma PlGF levels
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Plasma PlGF levels in pregnancies with other complications
Number of subjects: 177
Study: 11876696

Group type: EXPERIMENTAL
Intervention: Chewable CaCO3 tablets (750 mg, 1500 mg, 3000 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Effervescent bicarbonate solution
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Swallowable CaCO3 tablets
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9568857

Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Bicarbonate haemodialysis (BHD)
Number of subjects: 41
Study: 7839963

Group type: EXPERIMENTAL
Intervention: iohexol 300 at 60 sec delay
Number of subjects: 169

Group type: COMPARATOR
Intervention: iohexol 300 at 45 sec delay
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: ioversol 240 at 60 sec delay
Number of subjects: 169

Group type: COMPARATOR
Intervention: ioversol 240 at 45 sec delay
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: ioversol 320 at 60 sec delay
Number of subjects: 169

Group type: COMPARATOR
Intervention: ioversol 320 at 45 sec delay
Number of subjects: 169
Study: 2296985

Group type: EXPERIMENTAL
Intervention: Oral vitamin A (200,000 IU)
Number of subjects: 1772

Group type: COMPARATOR
Intervention: Control group (aged 3-5 years)
Number of subjects: 1772

Group type: EXPERIMENTAL
Intervention: Children aged 1-2 years
Number of subjects: 1772
Study: 153679

Group type: EXPERIMENTAL
Intervention: Clofezone (1200 mg for the first week, 600 mg for the second week)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Diclofenac (150 mg for the first week, 75 mg for the second week)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Clofezone vs Diclofenac
Number of subjects: 29

Group type: COMPARATOR
Intervention: Clofezone and Diclofenac
Number of subjects: 29
Study: 7223751

Group type: EXPERIMENTAL
Intervention: Oral administration of allopurinol tablets (300 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cocoa butter suppositories (300 mg allopurinol)
Number of subjects: 5

Group type: COMPARATOR
Intervention: PEG suppositories (300 mg allopurinol)
Number of subjects: 5
Study: 31709115

Group type: EXPERIMENTAL
Intervention: Low-dose Edaravone Dexborneol (12.5 mg)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Medium-dose Edaravone Dexborneol (37.5 mg)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: High-dose Edaravone Dexborneol (62.5 mg)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Edaravone (30 mg) - Control group
Number of subjects: 385
Study: 28199364

Group type: EXPERIMENTAL
Intervention: Low‐Molecular‐Weight Heparin (LMWH) - dalteparin (Fragmin®) 5000 IE once daily
Number of subjects: 63

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 63
Study: 25720712

Group type: EXPERIMENTAL
Intervention: Strengthened antihypertensive (intravenous antihypertensive drugs controlled at 130‐140 mmHg for 24 h)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal antihypertensive (intravenous antihypertensive drugs controlled at 160‐180 mmHg for 24 h)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Strengthened antihypertensive
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal antihypertensive
Number of subjects: 120
Study: 24088416

Group type: EXPERIMENTAL
Intervention: Fermented red ginseng (FRG) capsules
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 93
Study: 22324379

Group type: EXPERIMENTAL
Intervention: KW-7158 (oral administration)
Number of subjects: 0
Study: 19590350

Group type: EXPERIMENTAL
Intervention: Voucher redeemable for free safety devices and educational materials
Number of subjects: 542

Group type: COMPARATOR
Intervention: Safety device ownership
Number of subjects: 542

Group type: COMPARATOR
Intervention: Unsafe behaviors (stomach sleep position)
Number of subjects: 542
Study: 17516307

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) at 30 to 45 seconds
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC) at 5 to 10 seconds
Number of subjects: 65
Study: 15359179

Group type: EXPERIMENTAL
Intervention: Nurse case management and community health worker interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 12105831

Group type: EXPERIMENTAL
Intervention: Antibiotics (ciprofloxacin and metronidazole, both 500 mg twice daily) + budesonide (9 mg once daily)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo + budesonide (9 mg once daily)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Antibiotics (ciprofloxacin and metronidazole, both 500 mg twice daily)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 10527002

Group type: EXPERIMENTAL
Intervention: O'Brien‐Fleming method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pocock stopping boundaries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unplanned interim analyses
Number of subjects: 0
Study: 7782014

Group type: COMPARATOR
Intervention: Formalized follow-up protocols (e.g. bone scintigraphy, chest X-ray, abdominal ultrasound, mammography, laboratory investigations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed strategy based on meticulous history-taking and clinical examination with psychosocial rehabilitation emphasis
Number of subjects: 0
Study: 1704547

Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 14

Group type: COMPARATOR
Intervention: VVIR pacing
Number of subjects: 14
Study: 113807

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMI) 150 mg/day for 6 weeks
Number of subjects: 49
Study: 31451306

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 430

Group type: COMPARATOR
Intervention: No revascularization
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: PCI or CABG
Number of subjects: 430
Study: 28039551

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA) applied to the left dlPFC
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham control (not specified)
Number of subjects: 20
Study: 25465295

Group type: EXPERIMENTAL
Intervention: Housing First intervention
Number of subjects: 575

Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 575
Study: 23611977

Group type: EXPERIMENTAL
Intervention: Autologous UCB infusion, 1 year of daily oral vitamin D (2000 IU), and DHA (38 mg/kg) and intensive diabetes management
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intensive diabetes management alone
Number of subjects: 15
Study: 21808028

Group type: EXPERIMENTAL
Intervention: Exercise (45-min bout on an elliptical trainer)
Number of subjects: 12
Study: 19047656

Group type: EXPERIMENTAL
Intervention: Artekin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arterakine
Number of subjects: 0
Study: 16952492

Group type: EXPERIMENTAL
Intervention: 6-drug cocktail (flurbiprofen 50 mg, caffeine 100 mg, mephenytoin 100 mg, debrisoquin 10 mg, chlorzoxazone 250 mg, dapsone 100 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 5-drug cocktail (caffeine 100 mg, mephenytoin 100 mg, debrisoquin 10 mg, chlorzoxazone 250 mg, dapsone 100 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: flurbiprofen alone (50 mg)
Number of subjects: 24
Study: 15609591

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined Acupuncture-General Anesthesia (AGA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined Epidural-General Anesthesia (EGA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined Acupuncture-Drug Anesthesia (AA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined Acupuncture-Epidural-General Anesthesia (AEA)
Number of subjects: 0
Study: 12366880

Group type: EXPERIMENTAL
Intervention: Intermittent targeted therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous maintenance therapy
Number of subjects: 0
Study: 9468465

Group type: EXPERIMENTAL
Intervention: Antenatal thyrotropin-releasing hormone (400 microg each at eight-hour intervals, four doses)
Number of subjects: 996

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 996
Study: 7876650

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine by jet injector
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hepatitis A vaccine by needle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine by needle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both hepatitis vaccines by needle in separate arms
Number of subjects: 0
Study: 2137799

Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulfate (SLS) with addition of AEOS-7EO
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sodium lauryl sulfate (SLS) alone
Number of subjects: 21
Study: 389352

Group type: EXPERIMENTAL
Intervention: Metronidazole 2 g single dose
Number of subjects: 192

Group type: COMPARATOR
Intervention: Metronidazole 400 mg twice daily for five days
Number of subjects: 192
Study: 30649593

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU single bolus followed by 4,000 IU daily for 16 weeks)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 29512200

Group type: EXPERIMENTAL
Intervention: brodalumab 140 or 210 mg every 2 weeks (Q2W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: brodalumab 210 mg Q2W
Number of subjects: 0

Group type: COMPARATOR
Intervention: ustekinumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 26969136

Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) at 36°C
Number of subjects: 115

Group type: COMPARATOR
Intervention: Targeted temperature management (TTM) at 33°C
Number of subjects: 115
Study: 25194420

Group type: EXPERIMENTAL
Intervention: Interactive online decision aid (DA) for cholesterol self‐testing
Number of subjects: 1137

Group type: COMPARATOR
Intervention: Limited information sheet for cholesterol self‐testing (Control)
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: Interactive online decision aid (DA) for diabetes self‐testing
Number of subjects: 1137

Group type: COMPARATOR
Intervention: Limited information sheet for diabetes self‐testing (Control)
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: Cues to action in the cholesterol condition
Number of subjects: 1137
Study: 22558693

Group type: EXPERIMENTAL
Intervention: Hydrostatic pressure simulation at 20 cm pulpal pressure
Number of subjects: 3

Group type: COMPARATOR
Intervention: Hydrostatic pressure simulation but no pressure applied (positive control)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Conventional microleakage method
Number of subjects: 3
Study: 20932521

Group type: EXPERIMENTAL
Intervention: Cement augmentation technique (group A, 40 patients)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Gamma Nail conventional technique (group B, 40 patients)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cement augmentation technique (group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Gamma Nail conventional technique (group B)
Number of subjects: 80
Study: 17562493

Group type: EXPERIMENTAL
Intervention: GgHP (standardized herbal product from Galphimia glauca)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Lorazepam (1 mg)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: GgHP
Number of subjects: 152

Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 152
Study: 16231337

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 30
Study: 12375804

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study: 10481492

Group type: EXPERIMENTAL
Intervention: Bleomycin (added to one culture)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (no bleomycin added)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Laryngeal cancer patients with chromosome instability (b/c > 0.8)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Laryngeal cancer patients with chromosome oversensitivity to mutagens (b/c > 1)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Increased chromosome instability
Number of subjects: 61
Study: 7573998

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Epidural clonidine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both intravenous and epidural clonidine
Number of subjects: 24
Study: 2015917

Group type: EXPERIMENTAL
Intervention: Breast conserving treatment
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Simple mastectomy
Number of subjects: 163

Group type: COMPARATOR
Intervention: Choice of treatment
Number of subjects: 163
Study: 7166146

Group type: EXPERIMENTAL
Intervention: Success group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Failure group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hispanic subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: White subjects
Number of subjects: 0